Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort

Cancers

Norbert Jorch¹  Dominik T. Schneider²  Martina Becker³  Ulrich Hagenah⁴  Tobias R. Overbeck⁵  Nicole Heussen⁶  Ralf D. Hilgers⁶  Felix M. Mottaghy⁷  Beate Timmermann⁸  Waltraud Friesenbichler⁹  Gabriele Escherich^1,10  Tobias Feuchtinger^1,11  Holger Christiansen^1,12  Pablo Hernáiz Driever^1,13  Gabriele Kropshofer^1,14  Michael J. Eble^1,15  Hans Christiansen^1,16  Alexander Puzik^1,17  Hanna Kravets^1,18  Sabrina Franzen^1,18  Udo Kontny^1,18  Anna Makowska^1,18  Tristan Römer^1,18  Ahmed Farrag^1,18  Martina Bührlen^1,19  Jeanette Greiner^2,20  Wolfram Puppe^2,21  Triantafyllia Brozou^2,22  Stephan Tippelt^2,23  Gundula Staatz^2,24 

[1] Children Hematology and Oncology, Bethel, 33617 Bielefeld, Germany;Clinic of Pediatrics, University Witten/Herdecke, 44137 Dortmund, Germany;Department for Children and Adolescents, University Hospital Frankfurt, Goethe-University, 60590 Frankfurt am Main, Germany;Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of the RWTH Aachen, 52074 Aachen, Germany;Department of Hematology and Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany;Department of Medical Statistics, RWTH Aachen University Aachen, Pauwelsstrasse 19, 52074 Aachen, Germany;Department of Nuclear Medicine, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany;Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Centre (WTZ), 45147 Essen, Germany;Department of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Medical University of Vienna, 1090 Vienna, Austria;Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany;Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Dr von Hauner University Children’s Hospital, Ludwig Maximilian University, 80337 Munich, Germany;Department of Pediatric Oncology, Hematology and Hemostaseology, University Hospital Leipzig, 04103 Leipzig, Germany;Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany;Department of Pediatrics and Adolescent Medicine, Medical University, 6020 Innsbruck, Austria;Department of Radiation Oncology, RWTH Aachen University, 52074 Aachen, Germany;Department of Radiotherapy and Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany;Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany;Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany;Eltern-Kind-Zentrum Prof. Hess, Klinikum Bremen-Mitte, 28211 Bremen, Germany;Hematology and Oncology Department, Children’s Hospital of Eastern Switzerland, 9006 St. Gallen, Switzerland;Institute of Virology, Hannover Medical School, 30625 Hannover, Germany;Medical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children’s Hospital, Heinrich Heine University, 40225 Düsseldorf, Germany;Pediatric Oncology and Hematology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany;Section of Pediatric Radiology, University Medical Center Mainz, 55131 Mainz, Germany;

关键词: nasopharyngeal carcinoma;    platin-based chemotherapy;    radiotherapy;    interferon-beta;    late toxicities;    children;   

DOI  :  10.3390/cancers14051261

来源: DOAJ

【 摘 要 】

Nasopharyngeal carcinoma (NPC) in children and young adults has been treated within two consecutive prospective trials in Germany, the NPC-91 and the NPC-2003 study of the German Society of Pediatric Oncology and Hematology (GPOH). In these studies, multimodal treatment with induction chemotherapy, followed by radio (chemo)therapy and interferon-beta maintenance, yielded promising survival rates even after adapting total radiation doses to tumor response. The outcome of 45 patients in the NPC-2003 study was reassessed after a median follow-up of 85 months. In addition, we analyzed 21 further patients after closure of the NPC-2003 study, recruited between 2011 and 2017, and treated as per the NPC-2003 study protocol. The EFS and OS of 66 patients with locoregionally advanced NPC were 93.6% and 96.7%, respectively, after a median follow-up of 73 months. Seven patients with CR after induction therapy received a reduced radiation dose of 54 Gy; none relapsed. In young patients with advanced locoregional NPC, excellent long-term survival rates can be achieved by multimodal treatment, including interferon-beta. Radiation doses may be reduced in patients with complete remission after induction chemotherapy and may limit radiogenic late effects.

【 授权许可】

Unknown